menu
    • menu

    Company profile for RevBio

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    For RevBio, the revolution started here, in Massachusetts. It also started in nature with bio-inspiration from an amazing marine animal known as the Sandcastle Worm. Headquartered in Lowell, the company includes an extensive team of scientists, engineers, and clinicians who have reverse engineered a mineral-organic compound into a patented bioadhesive with an extensive platform of bone repair applications. A MassChallenge sta...
    For RevBio, the revolution started here, in Massachusetts. It also started in nature with bio-inspiration from an amazing marine animal known as the Sandcastle Worm. Headquartered in Lowell, the company includes an extensive team of scientists, engineers, and clinicians who have reverse engineered a mineral-organic compound into a patented bioadhesive with an extensive platform of bone repair applications. A MassChallenge start-up accelerator alum, RevBio has won over 10 grants, received multiple patents, and is conducting its first-in-human clinical trial on its biomimetic bone adhesive.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RevBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    600 Suffolk St. Suite #250 Lowell, MA 01854
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://revbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/revbio-inc/?viewAsMember=true
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/RevBio_

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Revbio's Crucial Trial For Cranial Flap Bone Glue
    FDA Approves Revbio's Crucial Trial For Cranial Flap Bone Glue

    28 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127271652/en/FDA-Greenlights-RevBios-Pivotal-Clinical-Trial-for-its-Cranial-Flap-Bone-Glue

    BUSINESSWIRE
    28 Jan 2026
    Share Share
    FDA Approves RevBio's Bone Glue for Regenerative Trials
    FDA Approves RevBio's Bone Glue for Regenerative Trials

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251219800454/en/RevBio-Receives-Approval-from-FDA-to-Start-a-Dental-Clinical-Trial-for-its-Regenerative-Bone-Glue

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Revbio Secures $2.2M NIH Grant For TETRANITE® In Spine Fractures
    Revbio Secures $2.2M NIH Grant For TETRANITE® In Spine Fractures

    06 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251006289642/en/RevBio-Receives-a-%242.2-Million-Phase-II-NIH-Grant-to-Further-Develop-the-Minimally-Invasive-Use-of-TETRANITE-to-Treat-Complex-Spine-Fractures

    BUSINESSWIRE
    06 Oct 2025
    Share Share
    RevBio Starts 2nd UK Trial of Bone Adhesive for Skull Repair
    RevBio Starts 2nd UK Trial of Bone Adhesive for Skull Repair

    29 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250529847431/en/RevBio-Expands-Globally-into-the-United-Kingdom-with-its-Second-Cranial-Flap-Fixation-Clinical-Trial-for-its-Regenerative-Bone-Adhesive

    BUSINESSWIRE
    29 May 2025
    Share Share
    RevBio Granted Patent For Regenerative Bone Adhesive Technology
    RevBio Granted Patent For Regenerative Bone Adhesive Technology

    30 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250128611777/en

    BUSINESSWIRE
    30 Jan 2025
    Share Share
    RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use
    RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use

    25 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231025796632/en

    BUSINESSWIRE
    25 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search